Full-Time

Senior Systems Analyst

Investor Support

Posted on 8/14/2025

Wellington Management

Wellington Management

1,001-5,000 employees

Global asset management for institutional clients

Compensation Overview

$80k - $180k/yr

+ Corporate Bonus + Incentives

Company Historically Provides H1B Sponsorship

Boston, MA, USA

Hybrid

Employees work from the office 4 days a week with flexibility to work remotely 1 day a week.

Category
Finance & Banking (2)
,
Required Skills
Bloomberg
Python
SQL
Risk Management
Oracle
Data Analysis
Requirements
  • Master’s degree in computer science, business, economics, finance, mathematical finance, or related subject
  • With two years of business analysis or systems analysis experience in trading, investment management, or financial services environment
  • Or a bachelor’s degree in related subject with five years of business analysis or systems analysis experience
  • Analytical and problem-solving skills in buy-side investment management systems and data technologies
  • Writing business requirements, functional specifications, use cases, and test plans
  • Business analysis or systems analysis experience in financial statement analysis, investment management or financial services environment
  • Experience with financial instruments including stocks, bonds, swaps, options, futures, forwards, derivatives, and FX
  • Experience with advanced investment data concepts including holdings, transactions, security master, analytics, and performance
  • Experience of investment workflows in the areas of research, valuation, analysis, risk management and portfolio construction
  • Experience writing SQL queries and working with database technologies such as Oracle or SQL Server
  • Experience working with Market Data platforms such as Bloomberg and FactSet
  • Experience with Python development
  • Client relationship skills
  • Experience working directly with business partners to understand their needs and deliver solutions that meet those needs
Responsibilities
  • Interact directly with investment professionals at all levels of the organization as a trusted advisor
  • Answer functional and technical questions from investment professionals about their tools, data, and reports in the areas of research, valuation, risk management, portfolio analysis and portfolio construction
  • Respond to requests from our business for ad hoc analysis as well as other information delivery solutions
  • Design, support, improve, and develop data validation and productivity tools and processes
  • Manage production incidents, determining root cause, appropriate corrective actions, and follow-up
  • Proactively identify issues and opportunities for improved methods and approaches to support investment processes
Desired Qualifications
  • Experience supporting investors – Proficient in the front and middle office functions of Order Management Systems
  • Experience working with investment tools, research tools, investment reporting, Factset/Bloomberg background
  • Experience with Fixed Income and Derivatives
  • Willingness to provide production support
  • Excellent communication and interpersonal skills as this person will be working directly with the users
Wellington Management

Wellington Management

View

Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

$60B

Headquarters

Boston, Massachusetts

Founded

1933

Simplify Jobs

Simplify's Take

What believers are saying

  • $1.19T AUM as of December 2024 supports scale across 50 countries.
  • Led Encord's $60M Series C to scale AI data platform in 2026.
  • Private credit market exceeds $30T, fueling 2023-launched capabilities.

What critics are saying

  • BlackRock's $11.5T AUM erodes active fees via ETF scale.
  • Renk's €300M blocked revenue writedowns 5.09% stake value.
  • Quince lawsuit triggers $50-100M liability on Series E investment.

What makes Wellington Management unique

  • Launched Absolute Return Global Equity Fund for market-neutral alpha in volatility.
  • Expanded private real estate credit platform in 2025 with Ravi S. Anand leading.
  • Manages $40B in alternatives across 40 funds for institutional clients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive health coverage

Work-life balance

Financial future

Development

Company News

Radio Intereconomía
Apr 14th, 2026
Wellington launches global market neutral fund to capture alpha in volatile environment

Wellington Management has launched the Wellington Absolute Return Global Equity Fund, a UCITS vehicle employing a global market neutral strategy aimed at generating returns above cash with limited exposure to traditional markets. The fund expands Wellington's liquid alternatives offering. The launch comes amid increased market volatility and reduced stability, positioning the fund to capture alpha in challenging conditions through its market-neutral approach to global equities.

AD HOC NEWS Portal Aktiengesellschaft
Apr 12th, 2026
Wellington buys 5% stake in Renk as $339M in delayed defence contracts weigh on cash flow

Wellington Management has acquired a 5.09% stake in German defence supplier Renk Group, signalling confidence despite the company facing significant operational challenges. The US asset manager built its position through direct share purchases and equity swaps. Renk is currently contending with approximately €300 million in blocked revenue due to delayed deliveries and missing export licenses. Around €200 million in planned sales has been pushed to 2026, whilst €80-100 million in orders for Israeli tank gearbox systems await German export approval. The cash flow pressure is evident, with free cash flow reaching only €67 million last fiscal year, well below the company's 80% conversion target. Shares fell 4.34% to €52.05, extending year-to-date losses to nearly 6%. Despite near-term challenges, Renk maintains a record order backlog of €6.68 billion.

Voyager Therapeutics
Apr 10th, 2026
Voyager Therapeutics Raises $60 Million in Oversubscribed Series B Financing | Voyager Therapeutics Inc.

Gene Therapy Leader to Advance Broad Product Pipeline & AAV Product Engine   Cambridge, Mass., April 13, 2015 – Voyager Therapeutics , a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today announced the successful

Business Wire
Apr 2nd, 2026
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and d...

医谷网
Mar 23rd, 2026
London gene therapy firm NightstaRx raises $45M to advance blindness treatment trials

NightstaRx, a London-based ophthalmology company developing gene therapies for inherited retinal diseases, has raised $45 million in Series C funding. Wellington Management Company and Redmile Group led the round, with participation from existing investors Syncona and New Enterprise Associates. Founded in 2013, Nightstar has four drug candidates targeting conditions including choroideremia, X-linked retinitis pigmentosa and macular degeneration. Its lead candidate, NSR AAV-REP1, uses an adeno-associated virus vector to deliver the REP-1 gene to retinal cells, potentially offering a one-time treatment for choroideremia, which causes progressive blindness. The therapy is currently in phase 1/2 trials, with positive results from 14 patients published in The Lancet. The funding will advance NSR AAV-REP1 into phase 3 trials and progress two other candidates into phase 1/2 studies.

INACTIVE